Abivax Sa Stock Current Valuation
| ABVX Stock | EUR 6.79 0.62 10.05% |
Valuation analysis of Abivax SA helps investors to measure Abivax SA's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Abivax SA's price fluctuation is relatively risky at this time. Calculation of the real value of Abivax SA is based on 3 months time horizon. Increasing Abivax SA's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Abivax SA is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Abivax Stock. However, Abivax SA's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.79 | Real 5.6 | Hype 6.79 | Naive 7.03 |
The real value of Abivax Stock, also known as its intrinsic value, is the underlying worth of Abivax SA Company, which is reflected in its stock price. It is based on Abivax SA's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Abivax SA's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Abivax SA helps investors to forecast how Abivax stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Abivax SA more accurately as focusing exclusively on Abivax SA's fundamentals will not take into account other important factors: Abivax SA Company Current Valuation Analysis
Abivax SA's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Abivax SA Current Valuation | 157.22 M |
Most of Abivax SA's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Abivax SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Abivax SA has a Current Valuation of 157.22 M. This is 98.91% lower than that of the Biotechnology sector and 96.62% lower than that of the Health Care industry. The current valuation for all France stocks is 99.05% higher than that of the company.
Abivax Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Abivax SA's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Abivax SA could also be used in its relative valuation, which is a method of valuing Abivax SA by comparing valuation metrics of similar companies.Abivax SA is currently under evaluation in current valuation category among its peers.
Abivax Fundamentals
| Return On Equity | -12.86 | |||
| Return On Asset | -0.44 | |||
| Operating Margin | 4.66 % | |||
| Current Valuation | 157.22 M | |||
| Shares Outstanding | 42.32 M | |||
| Shares Owned By Insiders | 2.46 % | |||
| Shares Owned By Institutions | 30.18 % | |||
| Price To Earning | (7.59) X | |||
| Price To Book | 22.19 X | |||
| Price To Sales | 3,840 X | |||
| Revenue | 37 K | |||
| Gross Profit | (45.52 M) | |||
| EBITDA | (42.25 M) | |||
| Net Income | (41.36 M) | |||
| Cash And Equivalents | 6 K | |||
| Cash Per Share | 1.28 X | |||
| Total Debt | 53.45 M | |||
| Debt To Equity | 31.40 % | |||
| Current Ratio | 2.20 X | |||
| Book Value Per Share | 0.36 X | |||
| Cash Flow From Operations | (45.66 M) | |||
| Earnings Per Share | (2.37) X | |||
| Target Price | 38.0 | |||
| Number Of Employees | 24 | |||
| Beta | 1.26 | |||
| Market Capitalization | 277.58 M | |||
| Total Asset | 110.36 M | |||
| Retained Earnings | (29 M) | |||
| Working Capital | 30 M | |||
| Current Asset | 34 M | |||
| Current Liabilities | 4 M | |||
| Z Score | 3.0 | |||
| Net Asset | 110.36 M |
About Abivax SA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Abivax SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abivax SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abivax SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Other Information on Investing in Abivax Stock
Abivax SA financial ratios help investors to determine whether Abivax Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Abivax with respect to the benefits of owning Abivax SA security.